Article

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

2012-11-16

Abstract excerpt

Abstract Abstract 675 Background: Activation of the p53 pathway by inhibition of its negative regulator MDM2 has been proposed as a novel strategy for cancer therapy. We report the final results of the Phase 1 leukemia trial of RG7112, a small molecule antagonist of MDM2 which activates p53 by disrupting the p53-MDM2 interaction. Methods: The trial was designed as a multi-center, open-label Phase 1 MAD study of pa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a9c50bf5-7e21-5e55-be31-0a400f482448
DOI: 10.1182/blood.v120.21.675.675

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute LeukemiaDOI 10.1182/blood.v120.21.675.675Read

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical DevelopmentSemantic proximity Read

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.Semantic proximity Read

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.Semantic proximity Read

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <i>MDM2</i> -Amplified and <i>TP53</i> Wild-type GlioblastomasSemantic proximity Read

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patientsSemantic proximity Read

MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance MechanismsSemantic proximity Read

Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer AgentsSemantic proximity Read

Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be AddressedSemantic proximity Read

A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in MiceSemantic proximity Read

P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic LeukemiaSemantic proximity Read

RNA-Sequencing Reveals Candidate Genes/Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic LeukemiaSemantic proximity Read

Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL -Rearranged Acute Lymphoblastic LeukemiaSemantic proximity Read